4ra5

Publication Abstract from PubMed

We previously demonstrated that selective inhibition of Protein Kinase C theta (PKCtheta) with triazinone 1 resulted in dose-dependent reduction of paw swelling in a mouse model of arthritis.1, 2 However, a high concentration was required for efficacy thus providing only a minimal safety window. Herein we describe a strategy to deliver safer compounds based on the hypothesis that optimizing potency in concert with good oral pharmacokinetic (PK) properties would enable in vivo efficacy at reduced exposures resulting in an improved safety window. Ultimately, transformation of 1 yielded analogues which demonstrated excellent potency and PK, and fully inhibited IL-2 production in an acute model. In spite of good exposure, twice-a-day treatment with 17l in the glucose-6-phosphate isomerase (GPI) chronic in vivo mouse model of arthritis yielded only moderate efficacy. On the basis of the exposure achieved, we conclude that PKCtheta inhibition alone is insufficient for complete efficacy in this rodent arthritis model.

Optimized Protein Kinase C theta (PKCtheta) Inhibitors Reveal Only Modest Anti-Inflammatory Efficacy in a Rodent Model of Arthritis.,George DM, Breinlinger EC, Argiriadi MA, Zhang Y, Wang J, Bansal-Pakala P, Duignan DB, Honore P, Lang Q, Mittelstadt S, Rundell L, Schwartz A, Sun J, Edmunds JJ J Med Chem. 2014 Sep 25. PMID:25254961^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.